NOV 15, 2018 10:30 AM PST

Management of HPV-Positive Women by QIAsure Methylation Test

Sponsored by: QIAGEN
Speaker

Abstract

Cervical cancer is the 4th most common cancer worldwide with 528,000 new cases and 266,000 deaths every year. It is also the only cancer 100% preventable. It has been extensively proved, that cervical cancer is caused by persistent infections with the human papilloma virus, termed high-risk HPV. In these persistent infections, there is a characteristic cumulative process called hypermethylation, which can eventually silence some critical tumour suppressor genes of the host cells.

Only around 20% of CIN2/3 lesions will progress to cancer, but still the majority of these are overtreated by ablative therapy leading to comorbidity, especially for women in their child bearing years. 

Hypermethylation of FAM 19A4 and miR124-2 have been shown to be reliable markers of disease progression, and can be used to determine if a CIN2/3 lesion is transforming into carcinoma.

QIAGEN´s QIAsure Methylation Test identifies cervical cancer and the preceding CIN lesion with high short-term progression risk. It has been validated in six different European screening settings as a triage test applicable for both HPV and/or cytology screened populations. It brings valuable benefits for the physician, the patient and has proven to improve cost effectiveness for health care organizations and insurance companies.


Show Resources
You May Also Like
OCT 05, 2022 9:00 AM PDT
C.E. CREDITS
OCT 05, 2022 9:00 AM PDT
Date: October 05, 2022 Time: 11:00am (PST), 2:00pm (EST), 8:00pm (CEST) Candida auris is a multi-drug resistant yeast that continues to be a global threat for infection and transmission in h...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
FEB 24, 2022 10:00 AM PST
C.E. CREDITS
FEB 24, 2022 10:00 AM PST
Date: February 24, 2021 Time: 10:00am (PST), 1:00pm (EST) One of the largest global public health crises is the rise of antimicrobial-resistant infections. Globally, over 700,000 people die...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
NOV 15, 2018 10:30 AM PST

Management of HPV-Positive Women by QIAsure Methylation Test

Sponsored by: QIAGEN


Show Resources
Loading Comments...
Show Resources